Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for alzheimer’s disease

13Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The search for new, robust, and reproducible biomarkers for Alzheimer’s disease (AD) diagnosis is a challenge. We recently reported that salivary lactoferrin (Lf) could be presented as new biomarker candidate for AD, being both non-invasive and cost-effective, as well as having appropriate diagnostic performance for the clinical detection of AD subjects. Saliva is an attractive sample type for biomarker-based testing approaches for several other diseases; however, its composition may change under certain circumstances. It is therefore critical to maintain a consistent salivary handling protocol, considering possible extrinsic factors that may influence salivary Lf concentration. In this work, we analyzed salivary Lf concentration under different handling conditions and donor-dependent factors including age, inter-diurnal variations, physical activity, and pharmacological treatments. Our aim was to evaluate the influence of such conditions on salivary Lf concentration. In conclusion, we found that most of these extrinsic factors should be considered in the future when using Lf as a predictive biomarker for AD.

Cite

CITATION STYLE

APA

Bartolome, F., Orive, G., & Carro, E. (2021). Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for alzheimer’s disease. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring, 13(1). https://doi.org/10.1002/dad2.12173

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free